Sky Century Investment, Inc. (SKYI) Fair Value 2026

SKYI · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Sky Century Investment, Inc. (SKYI) trades at $0.14, versus $0.05 from the Bayesian DCF — the only model with a usable estimate for SKYI. QOC: 5.2/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
SKYI
Price
$0.14
Quality Score
5.2/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give SKYI?

1 Intrinsic Value Models vs. Current Price ($0.14)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.05 -66.9%

All Models Active

All 1 models are displayed above.

What Is Sky Century Investment, Inc. (SKYI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sky Century Investment, Inc.'s intrinsic value is estimated at $0.05. Trading at its current price of $0.14, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -66.9%.

What Do the Models Say About SKYI?

1 of 13 models are currently active for SKYI. All 1 active models suggest the stock trades above fair value. One component of that median, the Bayesian DCF, returns $0.05 on its own, implying -66.9% downside from the current price. See which stocks rank higher →

How Does SKYI Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, SKYI ranks #73 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Sky Century Investment, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is SKYI a Value Trap?

CirclFi's Value Trap algorithm assigns SKYI a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Sky Century Investment, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Sky Century Investment, Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SKYI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SKYI's 1 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sky Century Investment, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

INMInMed Pharmaceuticals Inc.QOC 5.2IMCCIM Cannabis Corp.QOC 5.2CGCCanopy Growth CorporationQOC 5.3AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1YCBDcbdMD, Inc.QOC 5.3NTRRNeutra Corp.QOC 5.1SHPHShuttle Pharmaceuticals Holdings, Inc.QOC 3.6KNSAKiniksa Pharmaceuticals International, plcQOC 8.1ZYBTZhengye Biotechnology Holding LimitedQOC 6.2UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: INM · IMCC · CGC · AMLX · YCBD · NTRR · SHPH · KNSA · ZYBT · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to SKYI?

7 companies across all industries closest to SKYI’s Quality of Company score of 5.2/10.

WASTWaste Energy Corp.QOC 5.2TUSKMammoth Energy Services, Inc.QOC 5.2GLUThe Gabelli Global Utility & Income TrustQOC 5.2ASTCAstrotech CorporationQOC 5.2CNETZW Data Action Technologies Inc.QOC 5.2IDAIT Stamp Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: WAST · TUSK · GLU · ASTC · CNET · IDAI · NVDA

Where Does SKYI Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

SKYI is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Sky Century Investment, Inc.’s Valuation?

What is Sky Century Investment, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Sky Century Investment, Inc. (SKYI). One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.05 on its own. The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SKYI overvalued or undervalued right now?

At $0.14, 0 of 1 active models suggest SKYI may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Sky Century Investment, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.2 mean for SKYI?

Sky Century Investment, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SKYI?

CirclFi analyzes SKYI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SKYI a value trap in 2026?

Sky Century Investment, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Sky Century Investment, Inc. (SKYI) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/SKYI/ · Methodology
Primary sources for this SKYI valuation
  • Financial statements: Sky Century Investment, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001555017) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SKYI as of ; valuations recomputed .